ArticleCureus2025
Systemic Effects of Anabolic-Androgenic Steroid Abuse: A Case in Primary Care.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anabolic-androgenic steroid (AAS) abuse is a growing public health concern due to its wide-ranging physical and psychological effects. This case report highlights the multisystemic consequences of prolonged AAS use in a 30-year-old male presenting initially with a minor respiratory infection during a consultation in his healthcare center. Despite his primary complaint, upon physical examination, muscle hypertrophy, bilateral gynecomastia, and suspected testicular atrophy were observed, prompting further investigation. Laboratory findings showed high levels of testosterone, suppressed gonadotropins, elevated estradiol, dyslipidemia, and liver enzyme elevation, consistent with chronic AAS abuse. Imaging confirmed gynecomastia, and the patient was diagnosed with hypertension, likely secondary to AAS use. Despite counseling on the potential short- and long-term health risks, the patient chose to continue AAS use. Ongoing follow-up in primary care, however, made it possible for the patient to return to care after one year, when he presented with depressive symptoms and body image dissatisfaction following steroid cessation, demonstrating the critical role of family physicians in early detection, patient education, and motivational support. This case shows the importance of a thorough approach in identifying AAS abuse and managing its systemic effects to mitigate potentially perilous health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.